9/5/2014
1
Opening the Way for Medication-Assisted Treatment
in Family Drug Courts
Closed Doors or Welcome Mat?
Oklahoma Specialty Court Conference Thursday September 11, 2014
Erin Hall MSOT| Hon. Kyle B. HaskinsPresenters
This project is supported by Award No. 2013‐DC‐BX‐K002 awarded by the Office of Juvenile Justice and Delinquency Prevention Office of Justice Programs. The opinions, findings, and conclusions or recommendations expressed in this
publication are those of the author(s) and do not necessarily reflect the views of the Department of Justice
1
Who is here today?
2
The Need for Medication-Assisted Treatment (MAT)
3 4
9/5/2014
2
The Prescription Drug Abuse Problem
• 478millionprescriptionsforcontrolled‐substancesdispensedinU.S.in2010• 7millionAmericansreportedcurrentnon‐medicaluseofprescriptiondrugs
in2010• In2010,2millionpeoplereportedusingprescriptionpainkillersnon‐
medicallyforthefirsttimewithinthelastyear—nearly5,500aday• 1in4peopleusingdrugsforfirsttimein2010beganbyusingaprescription
drugnon‐medically• 6oftop10abusedsubstancesamonghighschoolseniorsareprescription
drugs
5
Trends in Emergency Department Visits Involving the Non-medical Use of Opioid Pain Relievers: 2004-2011
0
100000
200000
300000
400000
500000
600000
2004 2005 2006 2007 2008 2009 2010 2011
Num
berofEDVisits
Source:2011SAMHSADrugAbuseWarningNetwork(DAWN)
EDvisitsinvolvingthemisuseorabuseofopioidpainrelieversrose183%from2004to2011.
6
Overall Female Treatment Admissions for Other Opiates* as Primary Substance of Abuse
1.9%
8.4%
11.9%
0
2
4
6
8
10
12
14
1998 2008 2011
Percent
Year
Retrieved 09/05/13 fromhttp://wwwdasis.samhsa.gov/webt/newmapv1.htm*Other opiates includes non-prescription use of methadone, codeine, morphine, oxycodone, hydromorphone, meperidine, opium, and other drugs with morphine-like effects. 7
What is MAT?
8
9/5/2014
3
9
ASAM Definition of Addiction
“Addictionisaprimary,chronicdiseaseofbrainreward,motivation,memoryandrelatedcircuitry.Dysfunctioninthesecircuitsleadstocharacteristicbiological,psychological,socialandspiritualmanifestations.Thisisreflectedinanindividualpathologicallypursuingrewardand/orreliefbysubstanceuseandotherbehaviors.”
AdoptedbytheASAMBoardofDirectors4/12/2011
A Chronic, Relapsing Brain Disease•Brainimagingstudiesshowphysicalchangesinareasofthebrainthatarecriticalto• Judgment
• Decisionmaking
• Learningandmemory
• Behaviorcontrol
•Thesechangesalterthewaythebrainworks,andhelpexplainthecompulsionandcontinuedusedespitenegativeconsequences
SubstanceUseDisordersaresimilartootherdiseases,suchasheartdisease.Bothdiseasesdisruptthenormal,healthyfunctioningoftheunderlyingorgan,haveseriousharmfulconsequences,arepreventable,treatable,andifleftuntreated,canresultinprematuredeath
What is Medication-Assisted Treatment (MAT)?
• MATistheuseofmedications,incombinationwithcounselingandbehavioraltherapies,toprovideawhole‐patientapproachtothetreatmentofsubstanceusedisorders(SAMHSA,n.d.)
• MATisclinicallydrivenwithafocusonindividualizedpatientcare
• Researchshowsthatwhentreatingsubstance‐usedisorders,acombinationofmedicationandbehavioraltherapiesismostsuccessful
12
9/5/2014
4
Three FDA-approved Medications for Opioid Addiction
•Methadone‐ Dolophine®
•Buprenorphine – Suboxone,® Subutex®
•Naltrexone• oral– ReVia,®Depade®• extendedreleaseinjection‐ Vivitrol®‐
13
EH1
Opioid Agonist v. Antagonist
14
Source: retrieved from http://www.vivitrol.com/opioidrecovery/howvivitrolworks15
• Accesschallenges• Dailydosesatclinic• Diversioncanbeaconcern
16
• Effectivenessiswelldocumented:‐ Withdrawalsymptomsuppression‐ Patientretention‐ Reductionofopioiduse‐ Reductionofopioid‐relatedhealthandsocialproblems(i.e.crime)
Methadone
9/5/2014
5
•Availablefromprimaryandgeneralistphysicianswithwaiver
•Betteraccess
•Higheffectiveness
•Lowerdiversionrisk(butstillsomerisk)
•Noeupohoria,lowerstreetvalue
Buprenorphine
17
Naltrexone
•Monthlydosage•Canbeprescribedbyanyhealthcareproviderwithprescriptionauthority•Canonlybeusedwithfullydetoxifiedpatients,causesimmediatewithdrawalifopiatestillinsystem
•Nodiversionrisk•Lesseffectiveforopioidaddiction(betterforalcohol)
Vivitrol
18
How do we know it works?
Aspartofacomprehensivetreatmentprogram,MAThasbeenshownto:• Improvesurvival
• Increaseretentionintreatment
•Decreaseillicitopiateuse
•Decreasecriminalactivities
• Increaseemployment
• Improvebirthoutcomesamongopioiddependentpregnantwomen
19
MAT is only part of the solution
20
9/5/2014
6
Source: retrieved from http://www.vivitrol.com/opioidrecovery/howvivitrolworks21
Comprehensive Treatment
22
• Counseling – individual and group• Drug testing• Trauma/mental health care• Primary healthcare• Intensive case management• Relapse prevention• Aftercare• What else do you consider comprehensive treatment?
Does your FDC provide
comprehensive treatment?
23
If we know MAT works why aren’t
FDCs using it?24
9/5/2014
7
MAT & Drug Courts
• Arecentnationalsurveyfoundthatnearlyhalfofdrugcourtsdonotusemedicationsintheirprograms(Matusow etal,2013)
• Oneoftheprimarybarrierstousingmedicationswasreportedlyalackofawarenessoforfamiliaritywithmedicaltreatments
• Needforsubstantial,targetededucationalinitiativestoincreaseawarenessofthetreatmentandcriminaljusticebenefitsofMATinthedrugcourts
25
Why the Closed Doors?
1. Misconceptionofaddictionasamoralweaknessorwillfulchoice
2. Separationfromrestofhealthcare3. Languagemirrorsandperpetuates
stigma4. Failurebycriminaljusticesystemto
defertomedicaljudgmentintreatment
Stigma
Source:OlsenandShafstein,JAMA,201426
Why the Closed Doors?
1. Whencorrectlyprescribedandused:methadonedoesnotcreatea“high”
2. “Using”MATissimilarto“using”Prozactotreatdepressionorinsulintotreatdiabetes,notsimilarto“using”heroin
3. Addictionisatreatablediseaseofthebrainnotamoralfailingorachoice
Lack of knowledge
27
How do we incorporate MAT into
our family drug court?
28
9/5/2014
8
Without coordinated responses, families are not well served.
Different Agencies
Different Mandates
Different Organizations
Different ProvidersDifferent Goals
29
NADCP - MAT
In2012,theNADCPBoardofDirectorsissuedaunanimousresolution:
• MakereasonableeffortstoattainreliableexpertconsultationontheappropriateuseofMATfortheirparticipantsincludingpartneringwithsubstanceabusetreatmentprograms thatofferregularaccesstomedicalandpsychiatricservices.
• DonotimposeblanketprohibitionsagainsttheuseofMATfortheirparticipantsandthedecisionwhetherornottoallowtheuseofMATisbasedonaparticularizedassessmentineachcase.
30
1. DoesyourFDChaveapolicythataddressestheuseofMATforparents?Arethereconflictingpoliciesinpartneragencies(i.e.childwelfare)?
2. DoesyourFDChavearequirementofminimal“dosing”ordiscontinuanceofMATmedicationsforreunification?
3. DoesyourFDCuseMATasexclusionarycriteria?
4. DoesyourCWSsystemhaveaplanofsafecareforinfantsandmothersaffectedbyopioiduse?
Policy and Practice Issues
31
• Continuetoaccesseducationforallteammembers
• GettoknowthelocaloptionsforMAT
• TourMATprogramsandaskforanexplanationoftheirdosing&drugscreeningpractices
• HaveclientsignReleaseofInformationforMATprovidertofacilitateinformationsharing
• CreateawrittenpolicyforMAT
• EstablishcommunicationprotocolsacrossSAcounselors,MATproviders,court,childwelfareandotherteammembers
• InviteMATproviderstoparticipateinFDCstaffings
Recommendations for FDCs
32
9/5/2014
9
• Admissioncriteria– MATshouldnotbeanexclusionarycriteria
• ComprehensiveServices– MATshouldbepairedwith• Counseling,• Drugtestingandmonitoring,• Intensivecasemanagementandsupport(housing,employment,etc)
• Aftercare
Considerations for MAT policy for FDCs
33
• Coordinationandcommunicationwithprescribingphysiciansincluding:• Typeofmedication,dosageandfrequency• Attendanceatscheduledappointments• Parentbehaviorandpatternsofconcern
• CommunicationfromFDCtophysician• RequirementsofFDCparticipation• Parentbehaviorandpatternsofconcern(mayindicateneedtoadjustdosage)
Considerations for MAT policy for FDCs, Con’t
34
• Linkageswithotheragencies– dopartnershaveoutdatedandconflictingMATpolicies?
• Compliancemonitoring‐ specifywhoandhowwillthisbeaccomplished?
• Responsestobehavior– therapeutic,withconsiderationforstageofrecovery,phaseinFDC,etc.
Considerations for MAT policy for FDCs, Con’t
35
Special Considerations for Pregnant Women
36
9/5/2014
10
•Current (2012) standard of care for pregnant women with opioid dependence is referral for opioid-assisted therapy with methadone
•NAS is an expected and treatable condition that follows prenatal exposure to opioid agonists
Source: The American College of Obstetricians and Gynocolgoists. (2012) Committee Opinion No. 524: Opioid Abuse, Dependence, and Addiction in Pregnancy. Obstetrics & Gynecology, 119(5), 1070-1076.
37
MOTHERS StudyThe first randomized controlled trial data to support the safety and efficacy of bupernorphine. Findings include:
• Maternal outcomes, pain management considerations, and breastfeeding recommendations are similar between medications.
• Buprenorphine is an effective option for pregnant women who are new to treatment or maintained on buprenorphine pre‐pregnancy.
Hendree Jones, Presented at the NADCP Annual meeting, May 28, 2014, Anaheim, CA.
39 40
9/5/2014
11
Children and Recovering Mothers (CHARM) Overview
• A multidisciplinary group of agencies serving pregnant women with opiate addiction and their infants
• Provides comprehensive care coordination for pregnant women with opiate addiction and consultation for child welfare, medical, and addiction professionals across the state of Vermont
• The CHARM collaborative serves about 200 women and their infants annually.
41
Key Elements of CHARM
• In person meeting 2 hours each month
• Two year effort to create Memorandum or Understanding
• Team effort to engage women and get release of information singed
42
Key Elements of CHARM• Child welfare can begin providing services 30 prior to due
date
• State statute allows for Child Safety Teams to act on behalf of child safety
• 24/7 telephone support for families with infants needing methadone at home
43
The Tulsa Experience
Hon. Kyle B. Haskins
Opening the Doors in Family Drug Courts
44
9/5/2014
12
HastheTulsaCountyFDCalwaysbeenopentoMAT?
45
WhatweresomeofthekeybarriersinacceptingMATclientsinyourFDC?
46
WhyisitrecommendedthatFDCsnotconsiderMATasanexclusionarycriteria?
47
WhataresomeapproachesineducatingCWS,AOD,andCourtsregardingMAT?
48
9/5/2014
13
WhatarenextstepsinregardstopolicyandpracticeinvolvingMATclientsinyourFDC?
49
Next Steps & Resources
50
Todownload,pleasevisit:http://www.lac.org/doc_library/lac/publications/MAT_Report_FINAL_12‐1‐2011.pdf
LegalityofDenyingAccesstoMedicationAssistedTreatmentintheCriminalJusticeCenter(LegalJusticeCenter,December2011)
Resource
51
Resource
AdultDrugCourtBestPracticesStandards,SectionG,“Medications”,page44
DrugCourtJudicialBenchbook,VI.,Section4.14,“AddictionMedicine”,page76 52
9/5/2014
14
To download, please visit: www.ncsacw.samhsa.gov/files/Substance-Exposed-Infants.pdf
Resource
53
FDC LEARNING ACADEMY WEBINAR SERIESTHIS CHANGES EVERYTHING
in 2014Please join us
54
March 6th Tested and Proven – Utilization of Recovery Support Specialists as a Key Engagement and Retention Strategy in FDC (and Beyond)
April 10th Our Grant is Over – Now What? Re-financing and Re-Directing as Real Sustainability Planning for Your FDC
June 19th Closed Doors or Welcome Mat? Opening the Way for Mediction-Assisted Treatment in FDC
July 10th So How Do You Know They Are Really Ready? Key Considerations for Assessing Families in Recovery for Reunification
Aug. 14th Exploring Solutions Together – The Issue of Racial and Ethnic Disproportionality in FDCs
Sept. 18th Matching Service to Need – Exploring What “High- Risk, High-Need” Means for FDCs
This Changes Everything - 2014
55
Contact Information
Erin Hall, MSOT Hon. Kyle B. Haskins
Program AssociateChildren & Family Futures25371 Commercentre Dr.Suite 140 Lake Forest, CA 92630(714) 505‐[email protected]
Tulsa County Juvenile Bureau315 S. Gilcrease Museum Rd.14th Judicial Dist., State of OKTulsa, OK 74127 918‐596‐5910 [email protected]
56